GoalVest Advisory’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$22.3K Sell
924
-1,104
-54% -$28.9K ﹤0.01% 293
2026
Q1
$56.9K Sell
2,028
-275
-12% -$7.32K 0.01% 211
2025
Q4
$57.3K Buy
2,303
+1,240
+117% +$31.3K 0.01% 228
2025
Q3
$27.1K Hold
1,063
0.01% 274
2025
Q2
$25.8K Buy
1,063
+239
+29% +$5.57K 0.01% 256
2025
Q1
$20.9K Buy
824
+36
+5% +$942 0.01% 236
2024
Q4
$20.9K Sell
788
-93
-11% -$2.52K 0.01% 247
2024
Q3
$25.5K Hold
881
0.01% 248
2024
Q2
$24.6K Hold
881
0.01% 219
2024
Q1
$24.4K Sell
881
-196
-18% -$5.44K 0.01% 250
2023
Q4
$31K Buy
1,077
+811
+305% +$24.5K 0.01% 177
2023
Q3
$8.82K Sell
266
-26,431
-99% -$935K ﹤0.01% 302
2023
Q2
$979K Sell
26,697
-6,573
-20% -$256K 0.51% 31
2023
Q1
$1.36M Buy
33,270
+4,430
+15% +$191K 0.8% 22
2022
Q4
$1.48M Buy
28,840
+2,724
+10% +$131K 0.95% 18
2022
Q3
$1.14M Buy
26,116
+4,662
+22% +$227K 0.8% 25
2022
Q2
$1.11M Buy
21,454
+20,149
+1,544% +$1.03M 0.7% 40
2022
Q1
$68K Buy
+1,305
New +$67.7K 0.04% 145
2021
Q2
$39K Buy
+993
New +$38.6K 0.02% 157

Other funds holding PFE

GoalVest Advisory's PFE Position: Q2 2026 in Review

GoalVest Advisory reduced its Pfizer (PFE) stake by 54% in Q2 2026, selling an estimated $28.9K and leaving 924 shares worth $22.3K. The position accounts for ﹤0.01% of the portfolio, ranked #293.

GoalVest Advisory first reported a position in PFE in Q2 2021 and has held it in 19 quarters since. The position peaked at $1.48M in Q4 2022. 491 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • GoalVest Advisory held 924 shares of Pfizer worth $22.3K as of Q2 2026.
  • GoalVest Advisory sold 1,104 Pfizer shares in Q2 2026, an estimated $28.9K.
  • Pfizer made up ﹤0.01% of GoalVest Advisory's portfolio in Q2 2026, its #293 holding.
  • GoalVest Advisory first reported a position in Pfizer in Q2 2021 and has held it in 19 quarters since.
  • GoalVest Advisory's Pfizer position peaked at $1.48M in Q4 2022.
  • 491 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on GoalVest Advisory's 13F filing for Q2 2026, filed 9 Jul 2026.